EVOLUS INC (EOLS)
Sector: Health Care
2026 Annual Meeting Analysis
EVOLUS INC · Meeting: June 11, 2026
Directors FOR
0
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Brady Stewart and Vikram Malik as Class II Directors
Against Analysis
The 3-year TSR trigger fires (EOLS underperformed the peer group median by 24.2 percentage points, exceeding the 20pp threshold for companies with negative absolute returns), but the 5-year check shows EOLS actually outperformed the same peer group median over five years (+13.9pp), indicating the recent underperformance is a transient development within a longer track record of adequate relative performance — policy requires downgrading the vote to FOR in this circumstance.
The 3-year TSR trigger fires for Malik as well (same -24.2pp gap vs peer median, exceeding the 20pp threshold), but the 5-year relative TSR check shows EOLS outperformed the peer group median by 13.9 percentage points over five years, which means the longer track record is adequate and policy requires downgrading the vote to FOR — the recent 3-year trough appears to be a transient period rather than sustained multi-year destruction of value relative to peers.
For Analysis
Both Class II director nominees — Brady Stewart (director since 2022) and Vikram Malik (director since 2018, Chairman) — initially trigger a vote-against recommendation based on 3-year TSR underperformance versus the company's disclosed compensation peer group (EOLS lagged the peer median by 24.2 percentage points over three years, exceeding the 20-percentage-point threshold for companies with negative absolute returns). However, applying the required 5-year mitigant check, EOLS actually outperformed the same peer group median over five years by 13.9 percentage points, indicating the underperformance is a recent development rather than a sustained pattern. Policy requires downgrading both votes to FOR. No overboarding, attendance, independence, or other disqualifying issues were identified for either nominee.
Say on Pay
✓ FORCEO
David Moatazedi
Total Comp
$6,412,214
Prior Support
96%%
The CEO's total reported compensation of $6.4 million is consistent with a small-cap healthcare/commercial-stage company of Evolus's size and does not appear materially above benchmark for this title and market cap band. The pay mix is strongly weighted toward variable compensation — the proxy discloses that 88% of the CEO's 2025 target pay was 'at risk,' well exceeding the 50-60% variable pay threshold required by policy, and the program includes both performance-based stock awards (tied to revenue and operating profit goals over a two-year period) and time-based equity, with meaningful performance conditions. The prior-year Say on Pay vote received 96% support, the company holds a solid clawback policy aligned with SEC and Nasdaq requirements, and salary increases were frozen for all continuing executives for 2026 in recognition of challenging performance — all positive governance signals.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$2,510,000
Non-Audit Fees
$586,000
Non-audit fees (tax fees of $585,000 plus other fees of $1,000, totaling $586,000) represent approximately 23% of audit fees ($2,510,000), well below the 50% threshold that would raise independence concerns. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire and policy defaults to FOR. EY is a Big 4 firm appropriate for a company of Evolus's size and complexity, and no material financial restatements were identified.
Overall Assessment
The 2026 Evolus annual meeting features three standard proposals: director elections, auditor ratification, and an advisory Say on Pay vote. The two director nominees initially trigger a performance-based concern due to 3-year TSR underperformance versus peers, but the 5-year relative TSR mitigant applies for both, resulting in FOR votes across the full slate; the auditor and executive compensation program both pass policy screens cleanly.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing